HIF-2α as a possible therapeutic target of osteoarthritis

Osteoarthritis and Cartilage

Volumn 18, Issue 12, 2010, Pages 1552-1556

  Saito, T ^a   Kawaguchi, H ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

HIF 2 ; Osteoarthritis; Transcription factor

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; ARYL HYDROCARBON NUCLEAR TRANSLOCATOR LIKE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BIOLOGICAL FACTOR; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALPHA CHAIN; ARTICULAR CARTILAGE; BETA CHAIN; COHORT ANALYSIS; DRUG MECHANISM; ENCHONDRAL OSSIFICATION; GENE OVEREXPRESSION; HUMAN; KNEE OSTEOARTHRITIS; MECHANICAL STRESS; MOLECULE; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PEER REVIEW; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSACTIVATION;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARTILAGE DISEASES; CARTILAGE, ARTICULAR; HUMANS; OSSIFICATION, HETEROTOPIC; OSTEOARTHRITIS;

EID: 78649689772     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2010.10.006     Document Type: Review

References (56)

1. Hunter D.J., Felson D.T. Osteoarthritis. Br Med J 2006, 332:639-642.
2. Sharma L., Kapoor D. Epidemiology of osteoarthritis. Osteoarthritis, Diagnosis and Medical/Surgical Management 2007, 3-26. Lippincott Williams and Wilkins, Philadelphia. 4th edn. R.W. Moskowitz, R.D. Altman, M.C. Hochberg, J.A. Buckwalter, V.M. Goldberg (Eds.).
3. Glasson S.S., Askew R., Sheppard B., Carito B., Blanchet T., Ma H.L., et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005, 434:644-648.
4. Little C.B., Barai A., Burkhardt D., Smith S.M., Fosang A.J., Werb Z., et al. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum 2009, 60:3723-3733.
5. Stanton H., Rogerson F.M., East C.J., Golub S.B., Lawlor K.E., Meeker C.T., et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005, 434:648-652.
6. Burrage P.S., Brinckerhoff C.E. Molecular targets in osteoarthritis: metalloproteinases and their inhibitors. Curr Drug Targets 2007, 8:293-303.
7. Flannery C.R. Novel therapies in OA. Curr Drug Targets 2010, 11:614-619.
8. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69:562-573.
9. Boos N., Nerlich A.G., Wiest I., von der Mark K., Ganz R., Aebi M. Immunohistochemical analysis of type-X-collagen expression in osteoarthritis of the hip joint. J Orthop Res 1999, 17:495-502.
10. Cecil D.L., Appleton C.T., Polewski M.D., Mort J.S., Schmidt A.M., Bendele A., et al. The pattern recognition receptor CD36 is a chondrocyte hypertrophy marker associated with suppression of catabolic responses and promotion of repair responses to inflammatory stimuli. J Immunol 2009, 182:5024-5031.
11. Drissi H., Zuscik M., Rosier R., O'Keefe R. Transcriptional regulation of chondrocyte maturation: potential involvement of transcription factors in OA pathogenesis. Mol Aspects Med 2005, 26:169-179.
12. Johnson K.A., Terkeltaub R.A. External GTP-bound transglutaminase 2 is a molecular switch for chondrocyte hypertrophic differentiation and calcification. J Biol Chem 2005, 280:15004-15012.
13. Kamekura S., Hoshi K., Shimoaka T., Chung U., Chikuda H., Yamada T., et al. Osteoarthritis development in novel experimental mouse models induced by knee joint instability. Osteoarthritis Cartilage 2005, 13:632-641.
14. Kamekura S., Kawasaki Y., Hoshi K., Shimoaka T., Chikuda H., Maruyama Z., et al. Contribution of runt-related transcription factor 2 to the pathogenesis of osteoarthritis in mice after induction of knee joint instability. Arthritis Rheum 2006, 54:2462-2470.
15. Kawaguchi H. Endochondral ossification signals in cartilage degradation during osteoarthritis progression in experimental mouse models. Mol Cells 2008, 25:1-6.
16. Kawaguchi H. Regulation of osteoarthritis development by Wnt-beta-catenin signaling through the endochondral ossification process. J Bone Miner Res 2009, 24:8-11.
17. Kuhn K., D'Lima D.D., Hashimoto S., Lotz M. Cell death in cartilage. Osteoarthritis Cartilage 2004, 12:1-16.
18. von der Mark K., Kirsch T., Nerlich A., Kuss A., Weseloh G., Gluckert K., et al. Type X collagen synthesis in human osteoarthritic cartilage. Indication of chondrocyte hypertrophy. Arthritis Rheum 1992, 35:806-811.
19. Yamada T., Kawano H., Koshizuka Y., Fukuda T., Yoshimura K., Kamekura S., et al. Carminerin contributes to chondrocyte calcification during endochondral ossification. Nat Med 2006, 12:665-670.
20. Kronenberg H.M. Developmental regulation of the growth plate. Nature 2003, 423:332-336.
21. Saito T., Fukai A., Mabuchi A., Ikeda T., Yano F., Ohba S., et al. Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development. Nat Med 2010, 16:678-686.
22. Bracken C.P., Whitelaw M.L., Peet D.J. The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses. Cell Mol Life Sci 2003, 60:1376-1393.
23. Semenza G.L. HIF-1 and human disease: one highly involved factor. Genes Dev 2000, 14:1983-1991.
24. Lando D., Peet D.J., Whelan D.A., Gorman J.J., Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002, 295:858-861.
25. Schofield C.J., Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004, 5:343-354.
26. Ema M., Taya S., Yokotani N., Sogawa K., Matsuda Y., Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S A 1997, 94:4273-4278.
27. Patel S.A., Simon M.C. Biology of hypoxia-inducible factor-2alpha in development and disease. Cell Death Differ 2008, 15:628-634.
28. Tian H., Hammer R.E., Matsumoto A.M., Russell D.W., McKnight S.L. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 1998, 12:3320-3324.
29. Amarilio R., Viukov S.V., Sharir A., Eshkar-Oren I., Johnson R.S., Zelzer E. HIF1alpha regulation of Sox9 is necessary to maintain differentiation of hypoxic prechondrogenic cells during early skeletogenesis. Development 2007, 134:3917-3928.
30. Provot S., Schipani E. Fetal growth plate: a developmental model of cellular adaptation to hypoxia. Ann N Y Acad Sci 2007, 1117:26-39.
31. Schipani E., Ryan H.E., Didrickson S., Kobayashi T., Knight M., Johnson R.S. Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. Genes Dev 2001, 15:2865-2876.
32. Duval E., Leclercq S., Elissalde J.M., Demoor M., Galera P., Boumediene K. Hypoxia-inducible factor 1alpha inhibits the fibroblast-like markers type I and type III collagen during hypoxia-induced chondrocyte redifferentiation: hypoxia not only induces type II collagen and aggrecan, but it also inhibits type I and type III collagen in the hypoxia-inducible factor 1alpha-dependent redifferentiation of chondrocytes. Arthritis Rheum 2009, 60:3038-3048.
33. Pfander D., Cramer T., Schipani E., Johnson R.S. HIF-1alpha controls extracellular matrix synthesis by epiphyseal chondrocytes. J Cell Sci 2003, 116:1819-1826.
34. Stewart A.J., Houston B., Farquharson C. Elevated expression of hypoxia inducible factor-2alpha in terminally differentiating growth plate chondrocytes. J Cell Physiol 2006, 206:435-440.
35. Yang S., Kim J., Ryu J.H., Oh H., Chun C.H., Kim B.J., et al. Hypoxia-inducible factor-2alpha is a catabolic regulator of osteoarthritic cartilage destruction. Nat Med 2010, 16:687-693.
36. Hoffman E.C., Reyes H., Chu F.F., Sander F., Conley L.H., Brooks B.A., et al. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 1991, 252:954-958.
37. Gekakis N., Staknis D., Nguyen H.B., Davis F.C., Wilsbacher L.D., King D.P., et al. Role of the CLOCK protein in the mammalian circadian mechanism. Science 1998, 280:1564-1569.
38. Hirose K., Morita M., Ema M., Mimura J., Hamada H., Fujii H., et al. cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS factor (Arnt2) with close sequence similarity to the aryl hydrocarbon receptor nuclear translocator (Arnt). Mol Cell Biol 1996, 16:1706-1713.
39. Ikeda M., Yu W., Hirai M., Ebisawa T., Honma S., Yoshimura K., et al. cDNA cloning of a novel bHLH-PAS transcription factor superfamily gene, BMAL2: its mRNA expression, subcellular distribution, and chromosomal localization. Biochem Biophys Res Commun 2000, 275:493-502.
40. Maemura K., de la Monte S.M., Chin M.T., Layne M.D., Hsieh C.M., Yet S.F., et al. CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. J Biol Chem 2000, 275:36847-36851.
41. Hogenesch J.B., Chan W.K., Jackiw V.H., Brown R.C., Gu Y.Z., Pray-Grant M., et al. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J Biol Chem 1997, 272:8581-8593.
42. Hogenesch J.B., Gu Y.Z., Jain S., Bradfield C.A. The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors. Proc Natl Acad Sci U S A 1998, 95:5474-5479.
43. Powell W.H., Hahn M.E. Identification and functional characterization of hypoxia-inducible factor 2alpha from the estuarine teleost, Fundulus heteroclitus: interaction of HIF-2alpha with two ARNT2 splice variants. J Exp Zool 2002, 294:17-29.
44. Bunger M.K., Walisser J.A., Sullivan R., Manley P.A., Moran S.M., Kalscheur V.L., et al. Progressive arthropathy in mice with a targeted disruption of the Mop3/Bmal-1 locus. Genesis 2005, 41:122-132.
45. Yoshimura N., Muraki S., Oka H., Kawaguchi H., Nakamura K., Akune T. Cohort profile: research on osteoarthritis/osteoporosis against disability study. Int J Epidemiol 2010, 39:988-995.
46. Echtermeyer F., Bertrand J., Dreier R., Meinecke I., Neugebauer K., Fuerst M., et al. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat Med 2009, 15:1072-1076.
47. Lin A.C., Seeto B.L., Bartoszko J.M., Khoury M.A., Whetstone H., Ho L., et al. Modulating hedgehog signaling can attenuate the severity of osteoarthritis. Nat Med 2009, 15:1421-1425.
48. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16:4604-4613.
49. Akanji O.O., Sakthithasan P., Salter D.M., Chowdhury T.T. Dynamic compression alters NFkappaB activation and IkappaB-alpha expression in IL-1beta-stimulated chondrocyte/agarose constructs. Inflamm Res 2009, 59:41-52.
50. Nam J., Aguda B.D., Rath B., Agarwal S. Biomechanical thresholds regulate inflammation through the NF-kappaB pathway: experiments and modeling. PLoS One 2009, 4:e5262.
51. Coimbra I.B., Jimenez S.A., Hawkins D.F., Piera-Velazquez S., Stokes D.G. Hypoxia inducible factor-1 alpha expression in human normal and osteoarthritic chondrocytes. Osteoarthritis Cartilage 2004, 12:336-345.
52. Husa M., Liu-Bryan R., Terkeltaub R. Shifting HIFs in osteoarthritis. Nat Med 2010, 16:641-644.
53. Bohensky J., Terkhorn S.P., Freeman T.A., Adams C.S., Garcia J.A., Shapiro I.M., et al. Regulation of autophagy in human and murine cartilage: hypoxia-inducible factor 2 suppresses chondrocyte autophagy. Arthritis Rheum 2009, 60:1406-1415.
54. Siddiq A., Aminova L.R., Troy C.M., Suh K., Messer Z., Semenza G.L., et al. Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF- and CREB-independent pathways. J Neurosci 2009, 29:8828-8838.
55. Iliopoulos D., Malizos K.N., Oikonomou P., Tsezou A. Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. PLoS One 2008, 3:e3740.
56. Miyaki S., Nakasa T., Otsuki S., Grogan S.P., Higashiyama R., Inoue A., et al. MicroRNA-140 is expressed in differentiated human articular chondrocytes and modulates interleukin-1 responses. Arthritis Rheum 2009, 60:2723-2730.